ORIGINAL RESEARCH
Published on 09 Sep 2024
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States

doi 10.3389/fimmu.2024.1464092
- 1,499 views
- 3 citations
545
Total downloads
2,132
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: